Compare REAX & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REAX | CMPS |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 792.1M | 662.5M |
| IPO Year | N/A | 2020 |
| Metric | REAX | CMPS |
|---|---|---|
| Price | $3.67 | $7.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $5.90 | ★ $16.86 |
| AVG Volume (30 Days) | ★ 1.5M | 1.4M |
| Earning Date | 03-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,813,907,000.00 | N/A |
| Revenue This Year | $56.33 | N/A |
| Revenue Next Year | $21.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 65.60 | N/A |
| 52 Week Low | $3.39 | $2.25 |
| 52 Week High | $5.65 | $8.20 |
| Indicator | REAX | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 54.68 |
| Support Level | $3.53 | $6.91 |
| Resistance Level | $3.81 | $7.75 |
| Average True Range (ATR) | 0.19 | 0.51 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 18.87 | 47.41 |
The Real Brokerage Inc is a technology-powered real estate brokerage firm located in the United States and Canada. It has developed a proprietary transaction management and brokerage operations software called reZEN, which powers nearly all of its brokerage operations, enabling efficiency, automation, and flexibility by incorporating end-to-end transaction management, automated compliance and brokerage oversight, integrated payments and financial services, Leo CoPilot, and open API for customization. In addition, the company also offers mortgage brokering and title services. The company's operating segments are North American Brokerage, which derives key revenue, One Real Title, One Real Mortgage, and Real Wallet. Geographically, it derives key revenue from the United States.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.